Author response for "Characteristics and Risk Factors of Bortezomib Induced Peripheral Neuropathy: A Systematic Review of Phase III Trials"

2019 ◽  
Author(s):  
Tiffany Li ◽  
Hannah C. Timmins ◽  
Tracy King ◽  
Matthew C. Kiernan ◽  
David Goldstein ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Peripheral Neuropathy ◽  
Phase Iii ◽  
Author Response ◽  
Phase Iii Trials

Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials

2020 ◽  
Vol 38 (3) ◽  
pp. 229-243 ◽  
Author(s):  
Tiffany Li ◽  
Hannah C. Timmins ◽  
Tracy King ◽  
Matthew C. Kiernan ◽  
David Goldstein ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Peripheral Neuropathy ◽  
Phase Iii ◽  
Phase Iii Trials

Bortezomib Induced Peripheral Neuropathy: A Systematic Review of Phase III Trials

2019 ◽  
Vol 19 (10) ◽  
pp. e346
Author(s):  
Tiffany Li ◽  
Hannah Timmins ◽  
Tracy King ◽  
Matthew Kiernan ◽  
David Goldstein ◽  
...  
Keyword(s):  
Systematic Review ◽  
Peripheral Neuropathy ◽  
Phase Iii ◽  
Phase Iii Trials

The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials

2013 ◽  
Vol 46 (1) ◽  
pp. 275-284 ◽  
Author(s):  
Yuanshan Cui ◽  
Huantao Zong ◽  
Chenchen Yang ◽  
Huilei Yan ◽  
Yong Zhang
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Phase Iii Trials

Bayesian analysis from phase III trials was underused and poorly reported: a systematic review

2020 ◽  
Vol 123 ◽  
pp. 107-113 ◽  
Author(s):  
David Ferreira ◽  
Alexandre Vivot ◽  
Pierre Diemunsch ◽  
Nicolas Meyer
Keyword(s):  
Systematic Review ◽  
Bayesian Analysis ◽  
Phase Iii ◽  
Phase Iii Trials
Sign in / Sign up

Export Citation Format

Share Document